Abemaciclib in HR+, HER2- Breast Cancer: A Narrative Review of the Clinical Evidence - PubMed
4 hours ago
- #CDK4/6 Inhibitor
- #Breast Cancer Treatment
- #Abemaciclib
- Abemaciclib is a CDK4/6 inhibitor used with endocrine therapy for HR+, HER2- breast cancer.
- It improves survival and reduces recurrence in both early-stage (high-risk, node-positive) and advanced/metastatic disease.
- Effective with various endocrine therapies (aromatase inhibitors, tamoxifen, fulvestrant, imlunestrant) and as monotherapy, regardless of prior CDK4/6 exposure, mutation status, or endocrine resistance.
- Has a consistent safety profile, allowing long-term use, especially with dose-reduction strategies.
- Clinical trials support its role in enhancing endocrine therapy outcomes across the disease continuum.